Drug guidance
Disease-modifying therapies for treating multiple sclerosis
Condition
Blood and Immune System
Neurology
4 January 2022
Published on 04 Jan 2022
Last Updated on 04 Jan 2022
Guidance Recommendations
The Ministry of Health's Drug Advisory Committee has recommended:
Fingolimod 0.25 mg and 0.5 mg capsules for treating adults and children with relapsing-remitting multiple sclerosis, and
Siponimod 0.25 mg and 2 mg tablets for treating adults with secondary progressive multiple sclerosis with active disease evidenced by relapses or imaging features of inflammatory activity.
Subsidy status
Fingolimod 0.25 mg and 0.5 mg capsules and siponimod 0.25 mg and 2 mg tablets are recommended for inclusion on the Medication Assistance Fund (MAF) for the abovementioned indications.
MAF assistance does not apply to any formulations or strengths of alemtuzumab, cladribine, dimethyl fumarate, interferon beta-1a, natalizumab, ofatumumab or teriflunomide for treating adults or children with any form of multiple sclerosis.
Disease-modifying therapies for treating multiple sclerosis (4 Jan 2022) [PDF, 178 KB]
PES Disease-modifying therapies for treating multiple sclerosis (Published 4 Jan 2022) [PDF, 78 KB]